Case-control study of postmenopausal hormone replacement therapy and endometrial cancer

Brian L. Strom, Rita Schinnar, Anita L. Weber, Greta Bunin, Jesse A. Berlin, Mona Baumgarten, Angela DeMichele, Stephen C. Rubin, Michelle Berlin, Andrea B. Troxel, Timothy R. Rebbeck

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

This study evaluated recent inconsistent findings that adding progestins to postmenopausal estrogen replacement therapy protects against endometrial cancer. Using a population-based case-control study, the authors compared 511 endometrial cancer cases aged 50-79 years in the Philadelphia, Pennsylvania, region during 1999-2002 with 1,412 random-digit-dialing controls regarding postmenopausal hormone replacement therapy (HRT) use. Telephone interviews were performed with memory aids mailed in advance. An increased risk of endometrial cancer was observed among postmenopausal women using only unopposed estrogen for 3 or more years, compared with women who never used HRT (adjusted odds ratio = 3.4, 95% confidence interval (CI): 1.4, 8.3). Using combination HRT (of any duration) was associated with a substantial reduction in risk (odds ratio = 0.8, 95% CI: 0.6, 1.1). Comparing women using only combined estrogen and progestin for 3 or more years with women using only unopposed estrogen for 3 or more years, the authors found that the adjusted odds ratio was 0.2 (95% CI: 0.1, 0.6). Long-term use of unopposed estrogen is associated with increased risk for endometrial cancer, whereas combined estrogen plus progestin hormone therapy is not. Thus, if HRT is to be used in women with an intact uterus, this study confirms the benefit of adding progestins to the regimen.

Original languageEnglish (US)
Pages (from-to)775-786
Number of pages12
JournalAmerican Journal of Epidemiology
Volume164
Issue number8
DOIs
StatePublished - Oct 2006

Fingerprint

Estrogen Replacement Therapy
Endometrial Neoplasms
Case-Control Studies
Progestins
Estrogens
Hormone Replacement Therapy
Odds Ratio
Confidence Intervals
Uterus
Hormones
Interviews
Population

Keywords

  • Case-control studies
  • Endometrial neoplasm
  • Estrogens
  • Hormone replacement therapy
  • Progestins

ASJC Scopus subject areas

  • Epidemiology

Cite this

Strom, B. L., Schinnar, R., Weber, A. L., Bunin, G., Berlin, J. A., Baumgarten, M., ... Rebbeck, T. R. (2006). Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. American Journal of Epidemiology, 164(8), 775-786. https://doi.org/10.1093/aje/kwj316

Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. / Strom, Brian L.; Schinnar, Rita; Weber, Anita L.; Bunin, Greta; Berlin, Jesse A.; Baumgarten, Mona; DeMichele, Angela; Rubin, Stephen C.; Berlin, Michelle; Troxel, Andrea B.; Rebbeck, Timothy R.

In: American Journal of Epidemiology, Vol. 164, No. 8, 10.2006, p. 775-786.

Research output: Contribution to journalArticle

Strom, BL, Schinnar, R, Weber, AL, Bunin, G, Berlin, JA, Baumgarten, M, DeMichele, A, Rubin, SC, Berlin, M, Troxel, AB & Rebbeck, TR 2006, 'Case-control study of postmenopausal hormone replacement therapy and endometrial cancer', American Journal of Epidemiology, vol. 164, no. 8, pp. 775-786. https://doi.org/10.1093/aje/kwj316
Strom, Brian L. ; Schinnar, Rita ; Weber, Anita L. ; Bunin, Greta ; Berlin, Jesse A. ; Baumgarten, Mona ; DeMichele, Angela ; Rubin, Stephen C. ; Berlin, Michelle ; Troxel, Andrea B. ; Rebbeck, Timothy R. / Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. In: American Journal of Epidemiology. 2006 ; Vol. 164, No. 8. pp. 775-786.
@article{28b605365e394006b917ba79dc1f8216,
title = "Case-control study of postmenopausal hormone replacement therapy and endometrial cancer",
abstract = "This study evaluated recent inconsistent findings that adding progestins to postmenopausal estrogen replacement therapy protects against endometrial cancer. Using a population-based case-control study, the authors compared 511 endometrial cancer cases aged 50-79 years in the Philadelphia, Pennsylvania, region during 1999-2002 with 1,412 random-digit-dialing controls regarding postmenopausal hormone replacement therapy (HRT) use. Telephone interviews were performed with memory aids mailed in advance. An increased risk of endometrial cancer was observed among postmenopausal women using only unopposed estrogen for 3 or more years, compared with women who never used HRT (adjusted odds ratio = 3.4, 95{\%} confidence interval (CI): 1.4, 8.3). Using combination HRT (of any duration) was associated with a substantial reduction in risk (odds ratio = 0.8, 95{\%} CI: 0.6, 1.1). Comparing women using only combined estrogen and progestin for 3 or more years with women using only unopposed estrogen for 3 or more years, the authors found that the adjusted odds ratio was 0.2 (95{\%} CI: 0.1, 0.6). Long-term use of unopposed estrogen is associated with increased risk for endometrial cancer, whereas combined estrogen plus progestin hormone therapy is not. Thus, if HRT is to be used in women with an intact uterus, this study confirms the benefit of adding progestins to the regimen.",
keywords = "Case-control studies, Endometrial neoplasm, Estrogens, Hormone replacement therapy, Progestins",
author = "Strom, {Brian L.} and Rita Schinnar and Weber, {Anita L.} and Greta Bunin and Berlin, {Jesse A.} and Mona Baumgarten and Angela DeMichele and Rubin, {Stephen C.} and Michelle Berlin and Troxel, {Andrea B.} and Rebbeck, {Timothy R.}",
year = "2006",
month = "10",
doi = "10.1093/aje/kwj316",
language = "English (US)",
volume = "164",
pages = "775--786",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Case-control study of postmenopausal hormone replacement therapy and endometrial cancer

AU - Strom, Brian L.

AU - Schinnar, Rita

AU - Weber, Anita L.

AU - Bunin, Greta

AU - Berlin, Jesse A.

AU - Baumgarten, Mona

AU - DeMichele, Angela

AU - Rubin, Stephen C.

AU - Berlin, Michelle

AU - Troxel, Andrea B.

AU - Rebbeck, Timothy R.

PY - 2006/10

Y1 - 2006/10

N2 - This study evaluated recent inconsistent findings that adding progestins to postmenopausal estrogen replacement therapy protects against endometrial cancer. Using a population-based case-control study, the authors compared 511 endometrial cancer cases aged 50-79 years in the Philadelphia, Pennsylvania, region during 1999-2002 with 1,412 random-digit-dialing controls regarding postmenopausal hormone replacement therapy (HRT) use. Telephone interviews were performed with memory aids mailed in advance. An increased risk of endometrial cancer was observed among postmenopausal women using only unopposed estrogen for 3 or more years, compared with women who never used HRT (adjusted odds ratio = 3.4, 95% confidence interval (CI): 1.4, 8.3). Using combination HRT (of any duration) was associated with a substantial reduction in risk (odds ratio = 0.8, 95% CI: 0.6, 1.1). Comparing women using only combined estrogen and progestin for 3 or more years with women using only unopposed estrogen for 3 or more years, the authors found that the adjusted odds ratio was 0.2 (95% CI: 0.1, 0.6). Long-term use of unopposed estrogen is associated with increased risk for endometrial cancer, whereas combined estrogen plus progestin hormone therapy is not. Thus, if HRT is to be used in women with an intact uterus, this study confirms the benefit of adding progestins to the regimen.

AB - This study evaluated recent inconsistent findings that adding progestins to postmenopausal estrogen replacement therapy protects against endometrial cancer. Using a population-based case-control study, the authors compared 511 endometrial cancer cases aged 50-79 years in the Philadelphia, Pennsylvania, region during 1999-2002 with 1,412 random-digit-dialing controls regarding postmenopausal hormone replacement therapy (HRT) use. Telephone interviews were performed with memory aids mailed in advance. An increased risk of endometrial cancer was observed among postmenopausal women using only unopposed estrogen for 3 or more years, compared with women who never used HRT (adjusted odds ratio = 3.4, 95% confidence interval (CI): 1.4, 8.3). Using combination HRT (of any duration) was associated with a substantial reduction in risk (odds ratio = 0.8, 95% CI: 0.6, 1.1). Comparing women using only combined estrogen and progestin for 3 or more years with women using only unopposed estrogen for 3 or more years, the authors found that the adjusted odds ratio was 0.2 (95% CI: 0.1, 0.6). Long-term use of unopposed estrogen is associated with increased risk for endometrial cancer, whereas combined estrogen plus progestin hormone therapy is not. Thus, if HRT is to be used in women with an intact uterus, this study confirms the benefit of adding progestins to the regimen.

KW - Case-control studies

KW - Endometrial neoplasm

KW - Estrogens

KW - Hormone replacement therapy

KW - Progestins

UR - http://www.scopus.com/inward/record.url?scp=33749484600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749484600&partnerID=8YFLogxK

U2 - 10.1093/aje/kwj316

DO - 10.1093/aje/kwj316

M3 - Article

C2 - 16997897

AN - SCOPUS:33749484600

VL - 164

SP - 775

EP - 786

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 8

ER -